Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Isofol in connection with its listing on Nasdaq Stockholm
Mandate

Vinge advises Isofol in connection with its listing on Nasdaq Stockholm

October 21, 2021

Vinge has advised Isofol Medical AB in connection with its listing on Nasdaq Stockholm, with the first day of trading on 21 October 2021. The prospectus was approved by the Swedish Financial Supervisory Authority on 18 October 2021. Isofol has a market value corresponding to approximately SEK 1.5 billion.

Isofol is a biotech company in late clinical phase which develops arfolitixorin in order to improve standard treatment of 5-FE based chemotherapy, primarily for advanced colorectal cancer, by increasing tumour response and progression free survival.

Vinge’s team primarily consisted of Anders Strid, Jenny Sandlund and Edin Agic (Capital Markets), Victor Ericsson and Emelie Svanberg (Tax), Anna Ståhlklo (Commercial Agreements), Alexander Lindeberg (IP) and Rebecka Hansson (Employment Law).

Sanctions update April 14

 Further to our previous sanctions updates Sanctions update March 16, Sanctions Newsletter update 11 of March, Sanctions newsletter of 3 of March, Sanctions newsletter of 25 of February, we herewith provide a further update of recent sanctions developments following Russia’s war against Ukraine:
April 14, 2022

New guidance on sustainability agreements between competitors

 On 1 March 2022, the European Commission published draft revised guidelines on co-operation between competitors, together with draft revised block exemption regulations for specialisation agreements and R&D agreements. Unlike the current guidelines, which expire on 31 December 2022, the new guidelines include a chapter on the assessment of so-called sustainability agreements.
April 01, 2022

Vinge wins M&A legal advisor of the year award

 Mergermarket has awarded Vinge the Swedish Legal M&A Advisor of 2021.
April 01, 2022